drugset
drugset / Trial / NCT05017480

A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in China

NCT05017480 ↗

Phase 2 Completed 330 enrolled Connect Biopharm LLC
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the efficacy and safety of CBP-201 in Chinese subjects with moderate to severe atopic dermatitis.

Timeline

Start
2021-08-31
Primary completion
2022-12-01
Completion
2023-09-28

Drugs

EvaluationDrugModalityDoseRoute
Subject CBP-201 Unknown — Subcutaneous

Indications

atopic eczema